Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Amazon is Considering a $9 Billion Deal to Acquire Satellite Communications Company Globalstar. Here′s Why... (Fool) +++ GLOBALSTAR Aktie +3,82%

CSPC Aktie

 >CSPC Aktienkurs 
1.068 EUR    +0.6%    (TradegateBSX)
Ask: 1.097 EUR / 2000 Stück
Bid: 1.064 EUR / 2000 Stück
Tagesumsatz: 6958 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CSPC Aktie über LYNX handeln
>CSPC Performance
1 Woche: +16,2%
1 Monat: +2,3%
3 Monate: +16,1%
6 Monate: +2,3%
1 Jahr: +65,9%
laufendes Jahr: +14,9%
>CSPC Aktie
Name:  CSPC PHARMACEUTICAL GROUP
Land:  Hong Kong (China)
Sektor:  Gesundheit
ISIN/ Wkn:  HK1093012172 / 548183
Symbol/ Ticker:  CVG (Frankfurt)
Kürzel:  FRA:CVG, ETR:CVG, CVG:GR
Index:  -
Webseite:  https://www.cspc.com.hk/
Profil:  CSPC Pharmaceutical Group Ltd. is a prominent player in the pharmaceutical industry, focusing on the research, development, manufacture, and commercialization of a wide array of pharmaceutical products. Primarily engaged in innovative drug discovery ..
>Volltext..
Marktkapitalisierung:  12227.9 Mio. EUR
Unternehmenswert:  11393.51 Mio. EUR
Umsatz:  3137.93 Mio. EUR
EBITDA:  648.04 Mio. EUR
Nettogewinn:  467.12 Mio. EUR
Gewinn je Aktie:  0.04 EUR
Schulden:  79.47 Mio. EUR
Liquide Mittel:  754.82 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  0.87
Umsatzwachstum:  -21.11%
Gewinnwachstum:  -21.28%
Dividende je Aktie:  0.03 EUR
Dividendenrendite:  2.58%
Dividendenschätzung:  3.19%
Div. Historie:  17.10.25 - 0.0154616€
04.06.25 - 0.011044€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  CSPC
Letzte Datenerhebung:  03.04.26
>CSPC Kennzahlen
Aktien/ Unternehmen:
Aktien: 11522.5 Mio. St.
Frei handelbar: 67.74%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 19700
Umsatz/Mitarb.: 0.16 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 30.44%
Bewertung:
KGV: 25.99
KGV lG: 12.1
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: 17.58
Rentabilität:
Bruttomarge: 65.59%
Gewinnmarge: 14.89%
Operative Marge: 15.23%
Managementeffizenz:
Gesamtkaprendite: 8.46%
Eigenkaprendite: 11.78%
>CSPC Peer Group
Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, Nahrungsergänzungsmittel & Wellnessprodukte, Onkologie/ Krebs- Behandlung
 
31.03.26 - 16:30
CORNING JERRY and CSPC Collaboration on KN026 Clinical Study Achieves Primary Endpoint (AAStocks)
 
CORNING JERRY PHARMACEUTICALS-B (09966.HK) announced that the Phase III clinical study (KN026-004) of KN026 combined with docetaxel for injection (albumin-bound type-HB1801) for neoadjuvant treatment of human epidermal growth factor receptor 2 positive breast cancer, developed in collaboration with CSPC GROUP (01093.HK) subsidia......
31.03.26 - 06:45
Research: CMBI Lowers TP for CSPC Pharmaceutical to HKD8.7 as Global Expansion Accelerates (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
30.03.26 - 06:45
Research: BofAS Lowers TP for CSPC Pharmaceutical to HKD7.4, Raises Gross Margin Forecast, Reiterates 'Buy' (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
27.03.26 - 10:00
H Shrs: HSI Rises 95 Points Led by Pharma Stocks; CSPC Surges Nearly 14% (AAStocks)
 
US President Donald Trump extended the suspension of attacks on Iranian energy facilities until the 6th of next month, leading to a volatile rise in Hong Kong stocks. The HSI opened 87 points lower and initially fell 143 points to a low of 24,712 points, then rose 239 points to a high of 25,095 points, closing up 95 points or 0.......
27.03.26 - 06:00
H Shrs: HSI Rises 135 Points at Midday; BYD Surges Over 4%, CSPC Gains 10% (AAStocks)
 
US President Donald Trump extended the suspension of attacks on Iranian energy facilities until the 6th of next month, leading to a rise in the Hong Kong stock market in the morning session. The HSI opened 87 points lower and fluctuated, dropping 143 points to 24,712 points before closing at nearly the peak of 24,992 points at m......
27.03.26 - 05:15
Midday Takeaway: HSI Closes Midday at 24,992, Up 135 pts; HSTI Closes Midday at 4,811, Up 50 pts; CSPC PHARMA Up over 9%; XUNCE, WASION HOLDINGS, GANFENGLITHIUM, QINGSONG HEALTH, HUISHANG BANK Hit New Highs (AAStocks)
 
At midday close, HSI rose 135 pts or 0.5% to 24,992. HSTI rose 50 pts or 1.1% to 4,811. HSCEI gained 79 pts or 1.0% to 8,469.Active Heavyweights:MEITUAN (03690.HK) closed at $88.15, up 1.7%XIAOMI (01810.HK) closed at $32.98, up 1.7%BABA (09988.HK) closed at $123.4, up 0.3%TENCENT (00700.HK) closed at $495, down 0.1%HSI & HSCEI C......
27.03.26 - 04:00
Research: CMBI: CSPC External Licensing Could Be a Sustainable Revenue Growth Engine, Maintains 'Buy' Rating (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
27.03.26 - 03:45
Research: Nomura: CSPC Pharmaceutical Last Year's Net Profit Far Below Expectations Due to One-off Factors (AAStocks)
 
Nomura issued a research report stating that CSPC Pharmaceutical (01177.HK) saw its revenue increase by 10% year-on-year to RMB31.8 billion last year, aligning with management's guidance for double-digit growth and Nomura's expectations, but below the market forecast of RMB33.1 billion. Net profit fell by 33% year-on-year to RMB......
27.03.26 - 03:45
Research: BofAS Lowers TP for CSPC Pharmaceutical to HKD8, Rating 'Underperform' (AAStocks)
 
BofAS released a research report indicating that CSPC Pharmaceutical (01093.HK) recorded a total revenue of RMB26 billion last year, a year-on-year decrease of 10.4%, and a net profit of RMB3.9 billion, a year-on-year decrease of 10.3%. The firm expects CSPC Pharmaceutical's total cooperative revenue to exceed RMB10 billion this......
26.03.26 - 08:15
Research: Jefferies Raises TP for CSPC Pharmaceutical Group to HKD7.2, Maintains 'Underperform' Rating (AAStocks)
 
Jefferies published a research report stating that CSPC Pharmaceutical Group (01093.HK) still faced pressure in its performance last year, with annual revenue declining by 10% year-on-year to RMB260 billion, which was below expectations. Although management expects the finished drug business to return to positive growth this yea......
25.03.26 - 06:30
CSPC PHARMA Extends Gains to ~3%; 2025 Rev. Drops 10.4%, but Final DPS Added (AAStocks)
 
CSPC PHARMA (01093.HK) closed up 1% at midday. The Group announced at noon that its 2025 profit fell by 10.3%, but it increased its final dividend. The stock’s gains expanded in the afternoon session. It last printed at $8.57, jumping up 2.88%, with a trading volume of 54.0849 million shares, involving $460 million.CSPC PH......
25.03.26 - 05:45
Results: CSPC PHARMA Annual NP Sags 10.3%; Final DPS Adds to HKD0.15 (AAStocks)
 
CSPC PHARMA (01093.HK) announced its results for 2025, reporting revenue of RMB26.006 billion, down 10.4% YoY. Profit attributable to shareholders was RMB3.882 billion, down 10.3% YoY, with an EPS of RMB0.3398. A final DPS of HKD0.15 was declared, compared to HKD0.10 in the same period last year. Including the interim DPS of HKD......
12.03.26 - 09:15
Full-day Takeaway: HSI Closes at 25,716, Down 182 pts; HSTI Closes at 5,027, Down 27 pts; CSPC PHARMA Down over 4%; CNOOC, CHINA SHENHUA, CHINA RISUN GP, QINGSONG HEALTH, 160 HEALTH Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 182 pts or 0.7% to 25,716. HSTI dropped 27 pts or 0.5% to 5,027. HSCEI fell 4 pts or 0.1% to 8,699. Market turnover reached $242.18 billion.Active Heavyweights:BABA (09988.HK) closed at $131.6, down 1.2%TENCENT (00700.HK) closed at $546.5, down 1%MEITUAN (03690.HK) closed at $76.7, down 0.9%XIAOMI (01810.HK......
16.02.26 - 04:45
Research: Nomura Lifts CSPC PHARMA (01093.HK) TP to $12.04, Keeps Buy Rating (AAStocks)
 
Nomura issued a research report expecting that CSPC PHARMA (01093.HK)'s 4Q25 revenue will grow by 20% YoY to RMB7.6 billion, slightly higher than the market consensus of RMB7.4 billion. The broker also anticipated that the sales of finished drugs will ebb by 1% YoY to RMB5 billion, while collaboration revenue will be RMB1.1 ......
10.02.26 - 09:15
Full-day Takeaway: HSI Closes at 27,183, Up 155 pts; HSTI Closes at 5,451, Up 33 pts; CSPC PHARMA Up over 5%; ZTO EXPRESS-W, WH GROUP, BOC HONG KONG, WHARF REIC, HANG LUNG PPT Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 155 pts or 0.6% to 27,183. HSTI rose 33 pts or 0.6% to 5,451. HSCEI gained 74 pts or 0.8% to 9,242. Market turnover reached $234.04 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $88.8, down 2.5%BABA (09988.HK) closed at $160.5, up 1.6%TENCENT (00700.HK) closed at $551, down 1.6%XIAOMI (01810.HK) clo......
03.02.26 - 09:15
Full-day Takeaway: HSI Closes at 26,834, Up 59 pts; HSTI Closes at 5,467, Down 59 pts; CSPC PHARMA Up over 8%; NEW ORIENTAL, HSBC HOLDINGS, MTR CORPORATION, POWER ASSETS, CIMC Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 59 pts or 0.2% to 26,834. HSTI dropped 59 pts or 1.1% to 5,467. HSCEI fell 27 pts or 0.3% to 9,053. Market turnover reached $335.15 billion.Active Heavyweights:TENCENT (00700.HK) closed at $581, down 2.9%MEITUAN (03690.HK) closed at $93.2, down 1.7%BABA (09988.HK) closed at $161, down 1.4%XIAOMI (01810.HK) clo......
02.02.26 - 18:15
AZN Obesity Pipeline to Get a Boost From Deal With China′s CSPC (Zacks)
 
AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline....
02.02.26 - 06:00
Research: CICC Raises CSPC PHARMA (01093.HK) TP to $12, Anticipates Continued Out-licensing Realization (AAStocks)
 
CSPC PHARMA (01093.HK) and its subsidiaries authorized AstraZeneca to exclusively develop, produce and commercialize eight innovative long-acting peptide medicine projects globally, excluding mainland China and Hong Kong, Macau, and Taiwan, according to CICC's research report. This includes SYH2082 and three preclinical stag......
02.02.26 - 04:15
Research: BofAS Adds CSPC PHARMA (01093.HK) TP to $9.1, Keeps Underperform Rating on Sales Pressure (AAStocks)
 
CSPC PHARMA (01093.HK) reached an agreement with AstraZeneca to develop innovative long-acting peptide medicines, with the total value of the agreement potentially reaching up to US$18.5 billion, according to a research report issued by BofA Securities. Pursuant to the agreement, CSPC PHARMA will receive an upfront payment of US......
31.01.26 - 12:12
AstraZeneca obesity tie-up with CSPC seen as shrewd move (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Geizige Minister schaden dem Fürsten - allein sie sind unvermeidlich. - Königin Christine von Schweden
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!